1. News
  2. IRB Barcelona researcher Roger Gomis receives an award for his work on cancer

IRB Barcelona researcher Roger Gomis receives an award for his work on cancer

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab
Roger Gomis, head of the Growth Control and Cancer Metastasis Lab
2 Nov 2018

The Spanish Association of Cancer Research recognizes his work and grants him the ASEICA Young Investigator Award 2018.

The award ceremony will be held in Valencia on 6, 7 and 8 November.

The Spanish Association for Research on Cancer (ASEICA) has announced the winners of the 2018 ASEICA Awards, among them Roger Gomis, head of the Growth Control and Metastasis  lab at IRB Barcelona, who has received the Young Investigator Award in acknowledgement of his work on cancer.

ICREA researcher Roger Gomis leads a multidisciplinary lab devoted to metastasis research at IRB Barcelona. His work focuses on the identification and functional validation of the mechanisms that allow breast and colon cancer to metastasize to clinically relevant sites, and he has published various important articles in recent years.

“These awards aim to acknowledge the magnificent work that Spanish scientists are doing in spite of insufficient resources in the country,” said Carlos Camps, president of ASEICA.

The projects of the awardees will be presented in Valencia on 6,7 and 8 November in a gathering that will serve to disseminate advances in cancer research, present the most recent studies in the field, and showcase the work being undertaken on different types of tumour.

 

More information: http://www.aseica.es/

 

If you want to know more about the research that Roger Gomis lab does, you can watch the Meet Our Scientists Video "Light and credibility": https://www.youtube.com/watch?v
 

 

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 28 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).

cancer
metastasis
breast cancer
award

Related content

News

<p>Cancer cells with TLK inhibition show replication intermediates (green) at chromosome ends (red) - (IRB Barcelona)</p>

TLK protein inhibition activates the innate immune system

These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.

Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma.

The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.

<p>The discovered type of diffuse hypermutation is called "mutation fog". (Dave Hoefler, Unsplash)</p>

Mutations in cancer genomes: foggy with a chance of thunderstorms

The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.

Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.

Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.

<p>Immunofluorescence of a mouse mammary gland duct (IRB Barcelona)</p>

Identification of a determining factor in luminal cancer cells, that cause the greatest number of breast cancer cases

Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.

The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.